| Not Yet Recruiting | Cardiotoxicity Assessment and Reduction Through Exercise in BREAST Cancer NCT07405385 | University of Castilla-La Mancha | N/A |
| Not Yet Recruiting | Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Tria NCT07314853 | National Cancer Institute, Naples | N/A |
| Recruiting | EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study NCT07447089 | Università Cattolica di Milano | N/A |
| Recruiting | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma NCT07075185 | Kelonia Therapeutics, Inc. | Phase 1 |
| Recruiting | Preoperative Radiation Therapy and Immediate Breast Reconstruction NCT06739655 | Cancer Research Antwerp | N/A |
| Recruiting | Dream2Heal: An Adaptive Stepped-care Intervention for Chinese Cancer Survivors With Mild-to-moderate Insomnia NCT06813235 | The University of Hong Kong | N/A |
| Not Yet Recruiting | Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib NCT06754761 | AstraZeneca | Phase 1 |
| Recruiting | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies NCT06759649 | Compugen Ltd | Phase 1 |
| Recruiting | Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology. NCT06980012 | Polyclinique Lyon Nord | N/A |
| Recruiting | Development of a Platform for the Clinical Implementation of Precision Oncology in the Central-Southern Region NCT06894823 | National Cancer Institute, Naples | — |
| Recruiting | CARE Study: Cancer, Asian Americans, and Relationship Enrichment NCT06782581 | Fox Chase Cancer Center | N/A |
| Completed | A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Tr NCT05909202 | National Institutes of Health Clinical Center (CC) | N/A |
| Recruiting | Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention) NCT06672887 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 / Phase 3 |
| Completed | Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung C NCT07192926 | Ankara Etlik City Hospital | — |
| Terminated | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors NCT05429762 | Sanofi | Phase 1 |
| Enrolling By Invitation | Retrospective WGS Study NCT06820294 | The Wellcome Sanger Institute | — |
| Terminated | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumor NCT05450562 | Sanofi | Phase 1 / Phase 2 |
| Terminated | The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial NCT05101798 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Terminated | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Soli NCT05013554 | Sanofi | Phase 1 |
| Terminated | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced NCT04717375 | Sanofi | Phase 1 / Phase 2 |
| Unknown | Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment NCT02226289 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Completed | Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation NCT04142567 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Di NCT04138823 | Boehringer Ingelheim | Phase 1 |
| Terminated | Procalcitonin and Antimicrobial Utilization in Critically Ill Cancer Patients with Sepsis NCT04203524 | King Hussein Cancer Center | N/A |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Ant NCT03547037 | Janssen Pharmaceutical K.K. | Phase 1 |
| Terminated | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Pat NCT03637764 | Sanofi | Phase 1 / Phase 2 |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Terminated | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivo NCT03251924 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumo NCT03099161 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Assesment of the Implementation of a Therapeutic Educational Intervention Affecting Adherence to Oral Chemothe NCT02828449 | Institut de Cancérologie de la Loire | N/A |
| Completed | A Phase I Trial of HS-10241 in Solid Tumors NCT02759640 | Atridia Pty Ltd. | Phase 1 |
| Completed | Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban NCT02746185 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Natural History of and Specimen Banking for People With Tumors of the Central Nervous System NCT02851706 | National Cancer Institute (NCI) | — |
| Completed | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer NCT02747342 | Atridia Pty Ltd. | Phase 1 |
| Completed | Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data NCT02875327 | National Cancer Institute (NCI) | — |
| Recruiting | The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 | The Netherlands Cancer Institute | Phase 2 |
| Completed | A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Recept NCT02699606 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors NCT02759666 | Atridia Pty Ltd. | Phase 1 |
| Completed | A Study of SHR6390 in Advanced Solid Tumor Patients NCT02684266 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors NCT02743637 | SynDevRx, Inc. | Phase 1 |
| Withdrawn | Gorbly Compression Device for Use in Image-guided Procedures NCT02578667 | University of Miami | N/A |
| Completed | A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers NCT02514603 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of LY3023414 in Japanese Participants With Advanced Cancer NCT02536586 | Eli Lilly and Company | Phase 1 |
| Terminated | Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclopho NCT02434146 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | A Study of Galunisertib on the Immune System in Participants With Cancer NCT02304419 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of Olaratumab in Japanese Participants With Advanced Cancer NCT02377752 | Eli Lilly and Company | Phase 1 |
| Unknown | Effect of an Early Mobilization Program on Outcomes After Major Cancer Surgery NCT01693172 | Instituto do Cancer do Estado de São Paulo | N/A |
| Suspended | A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors NCT02354547 | SynerGene Therapeutics, Inc. | Phase 1 |
| Completed | The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN). NCT02309164 | University of Sao Paulo | N/A |
| Enrolling By Invitation | Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern NCT02154022 | National Cancer Institute (NCI) | — |
| Unknown | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics NCT02450175 | Sinai Hospital of Baltimore | N/A |
| Completed | A Study of LY2835219 in Participants With Cancer NCT02117648 | Eli Lilly and Company | Phase 1 |
| Completed | Current Practice Pattern and Effect of Training in Upper Endoscopic Biopsy NCT02044536 | Chuncheon Sacred Heart Hospital | — |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Completed | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patien NCT01920061 | Pfizer | Phase 1 |
| Completed | Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide NCT02394821 | University of Sao Paulo | Phase 3 |
| Completed | Modern Hybrid Imaging in Patients With OSCC NCT04280159 | Wuerzburg University Hospital | — |
| Completed | Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas NCT01794104 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (C NCT01708850 | London Health Sciences Centre | Phase 4 |
| Unknown | Epidemiological Study of Colorectal Cancer in WuHan NCT01863303 | Wuhan Pu-Ai Hospital | — |
| Completed | A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors NCT01517464 | SynerGene Therapeutics, Inc. | Phase 1 |
| Completed | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Part NCT01425008 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | ECI301 and Radiation for Advanced or Metastatic Cancer NCT01441115 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions NCT01457196 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Completed | Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases NCT01395407 | Emory University | Phase 1 |
| Completed | The Use of Angiotensin Receptor Blockers and the Risk of Cancer NCT02215733 | Boehringer Ingelheim | — |
| Terminated | Comparing Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures NCT01287013 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | Evaluating Biobanking Educational Tools NCT01672944 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced S NCT01155713 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy NCT01287286 | Chang Gung Memorial Hospital | Phase 2 / Phase 3 |
| Completed | Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) NCT01092091 | Bio-Cancer Treatment International Limited | Phase 1 / Phase 2 |
| Completed | EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients NCT01942005 | Andreas Arnold | — |
| Terminated | Use of PET Imaging to Distinguish Malignant From Benign IPMN NCT01104116 | Columbia University | N/A |
| Completed | Facts and Attitudes About Clinical Trials NCT01269645 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PE NCT00961831 | Bayer | Phase 1 |
| Completed | Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN) NCT01104077 | Columbia University | — |
| Completed | Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) NCT00694356 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Side Population in Pancreatic Ductal Adenocarcinoma (PDAC) NCT00936104 | University Hospital, Gasthuisberg | — |
| Completed | Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) NCT00694083 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study of TRC102 in Combination With Pemetrexed in Cancer Patients NCT00692159 | Tracon Pharmaceuticals Inc. | Phase 1 |
| Completed | Study of Pegylated Human Recombinant Arginase for Liver Cancer NCT00988195 | Bio-Cancer Treatment International Limited | Phase 1 |
| Completed | Safety Study of Infusion of SGT-53 to Treat Solid Tumors NCT00470613 | SynerGene Therapeutics, Inc. | Phase 1 |
| Completed | Family-supported Smoking Cessation for Chronically Ill Veterans NCT00448344 | US Department of Veterans Affairs | N/A |
| Completed | The Samsung Medical Center Comprehensive Cancer Center Registry from 2008 to 2023 NCT06703957 | Samsung Medical Center | — |
| Unknown | Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery NCT00747292 | Minimal Access Therapy Training Unit | Phase 1 / Phase 2 |
| Completed | Study of ADI-PEG 20 in Patients With Advanced Melanoma NCT00520299 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Completed | MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) NCT00496353 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Rela NCT00505414 | Grünenthal GmbH | Phase 3 |
| Completed | Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies NCT01117623 | Bayer | Phase 1 |
| Completed | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products NCT00695279 | St. Jude Children's Research Hospital | — |
| Completed | Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Ca NCT00408434 | Daiichi Sankyo | Phase 1 |
| Completed | A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors NCT01105533 | Pfizer | Phase 1 |
| Terminated | Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer NCT00321958 | University of Maryland, Baltimore | — |
| Terminated | Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms NCT00408018 | Piramal Enterprises Limited | Phase 1 |
| Completed | PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma NCT00226005 | Pancreatic Cancer Research Team | Phase 2 |
| Completed | Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms NCT00407498 | Piramal Enterprises Limited | Phase 1 |
| Completed | A Phase II Study of Spinal Radiosurgery NCT00573872 | University of Alabama at Birmingham | N/A |
| Completed | Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With NCT00100139 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refra NCT00083720 | Eli Lilly and Company | Phase 2 |
| Completed | Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy NCT01163110 | Midwestern Regional Medical Center | Phase 1 |
| Completed | A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. NCT00199836 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tum NCT00143533 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer NCT00080418 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Extension Program for Bay 43-9006 NCT00657254 | Bayer | Phase 2 |
| Completed | Study of Karenitecin (BNP1350) to Treat Malignant Melanoma NCT00062491 | BioNumerik Pharmaceuticals, Inc. | Phase 2 |
| Completed | Process and Outcomes of Pain Management NCT00028249 | National Institutes of Health Clinical Center (CC) | — |
| Terminated | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas NCT00023166 | Enzon Pharmaceuticals, Inc. | Phase 1 |
| Completed | Iressa Expanded Access Program (EAP) NCT00034879 | AstraZeneca | Phase 3 |
| Completed | Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria NCT00004988 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Tr NCT00283465 | Janssen-Cilag B.V. | Phase 4 |
| Completed | Oxaliplatin in Cancer Patients With Impaired Kidney Function NCT00001835 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Rad NCT00026936 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trial NCT00001695 | National Cancer Institute (NCI) | — |
| Completed | Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Canc NCT00026897 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System NCT00026871 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tissue Acquisition for Molecular Diagnostics NCT00001580 | National Cancer Institute (NCI) | — |
| Completed | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype NCT00001572 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy NCT00270127 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits NCT00001500 | National Cancer Institute (NCI) | — |
| Completed | A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms NCT00001444 | National Cancer Institute (NCI) | Phase 1 |
| Completed | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy NCT00270166 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts NCT00026858 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced NCT00001341 | National Cancer Institute (NCI) | Phase 1 |
| Completed | In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients NCT00001336 | National Cancer Institute (NCI) | — |
| Completed | Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neo NCT00001150 | National Cancer Institute (NCI) | — |
| No Longer Available | Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients NCT02473497 | Pfizer | — |
| Completed | Effectiveness of the FairCare System for Patients With Advanced Illness NCT00105599 | US Department of Veterans Affairs | Phase 2 |
| No Longer Available | Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies NCT02955446 | University of Colorado, Denver | — |